Fda accepts dupixent® (dupilumab) for review in children with moderate-to-severe asthma

Tarrytown, n.y. and paris, march 4, 2021 /prnewswire/ -- submission supported by data demonstrating dupixent significantly reduced severe asthma attacks and is the only biologic to improve lung function in children aged 6 to 11 years in a randomized phase 3 trial dupixent has the...
REGN Ratings Summary
REGN Quant Ranking